Top Markets
#1 Palladium Network Palladium Network +27.92%
#2 Siren Siren +24.06%
#3 BankrCoin BankrCoin +20.27%
#4 MarsCoin MarsCoin +19.67%
#5 Ankr Network Ankr Network +18.93%
#6 Hive Hive +18.83%
#7 StonkBroker StonkBroker +14.43%
#8 Status Status +12.01%
#9 Prom Prom +11.13%
#10 Provenance Blockchain Provenance Blockchain +8.75%
Coin of the day
Palladium Network Palladium Network
Settings
Language
ENGLISH
Currency
USD
Theme
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
Rank in Stocks #18268
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Share Price
$1.79
Last synced: 2026-09-02
Market Cap
$205.75M
Change (1 day)
3.18%
Change (1 year)
-61.61%
Country
US
Trade NovaBridge Biosciences (NBP)

Category

Healthcare
Revenue for NovaBridge Biosciences (NBP)
Revenue in Sep 2026 TTM: 0
According to NovaBridge Biosciences latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for NovaBridge Biosciences from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH